Chemokine receptor 2 antagonist CCX140-B in Phase 2 for type 2 diabetes

被引：0
|
作者：
Sullivan, T. [1 ]
Miao, S. [1 ]
Berahovich, R. [1 ]
Zhao, N. [1 ]
Ungashe, S. [1 ]
Johnson, D. [1 ]
Bekker, P. [1 ]
Jean, J. [1 ]
Schall, T. J. [1 ]
机构：
[1] ChemoCentryx Inc, Mountain View, CA USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
883
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of oral chemokine receptor 2 antagonist CCX140-B in a phase 2 type 2 diabetes study
    Hanefeld, M.
    Schell, E.
    Gouni-Berthold, I.
    Melichar, M.
    Vesela, I.
    Sullivan, T.
    Miao, S.
    Johnson, D.
    Jaen, J. C.
    Schall, T. J.
    Bekker, P.
    DIABETOLOGIA, 2011, 54 : S87 - S87
  • [2] Oral Chemokine Receptor 2 Antagonist CCX140-B Shows Safety and Efficacy in Type 2 Diabetes Mellitus
    Hanefeld, Markolf
    Schell, Ernest
    Gouni-Berthold, Ioanna
    Melichar, Martin
    Vesela, Ivana
    Sullivan, Tim
    Miao, Shichang
    Johnson, Dan
    Jaen, Juan
    Bekker, Pirow
    Schall, Thomas J.
    DIABETES, 2011, 60 : A85 - A85
  • [3] CLINICAL DEVELOPMENT OF CCR2 ANTAGONISTS CCX140-B AND CCX872-B
    Bekker, Pirow
    Charvat, Trevor
    Miao, Shichang
    Dairaghi, Dan
    Lohr, Lisa
    Sullivan, Timothy
    Seitz, Lisa
    Miao, Zhenhua
    Powers, Jay
    Jaen, Juan
    Schall, Thomas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 17 - 17
  • [4] The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
    de Zeeuw, Dick
    Bekker, Pirow
    Henkel, Elena
    Hasslacher, Christopher
    Gouni-Berthold, Ioanna
    Mehling, Heidrun
    Potarca, Antonia
    Tesar, Vladimir
    Heerspink, Hiddo J. Lambers
    Schall, Thomas J.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 687 - 696
  • [5] CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
    Sullivan, Timothy
    Miao, Zhenhua
    Dairaghi, Daniel J.
    Krasinski, Antoni
    Wang, Yu
    Zhao, Bin N.
    Baumgart, Trageen
    Ertl, Linda S.
    Pennell, Andrew
    Seitz, Lisa
    Powers, Jay
    Zhao, Ruiping
    Ungashe, Solomon
    Wei, Zheng
    Boring, Landin
    Tsou, Chia-Lin
    Charo, Israel
    Berahovich, Robert D.
    Schall, Thomas J.
    Jaen, Juan C.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 305 (09) : F1288 - F1297
  • [6] Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase 2 Rheumatoid Arthritis Study
    Tak, Paul P.
    Balanescu, Andra
    Tseluyko, Vira
    Bojin, Silvia
    Drescher, Edit
    Dairaghi, Dan
    Miao, Shichang
    Marchesin, Vittorio
    Jaen, Juan
    Bekker, Pirow
    Schall, Thomas J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4046 - 4046
  • [7] An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes
    Sayyed, Sufyan G.
    Ryu, Mi
    Kulkarni, Onkar P.
    Schmid, Holger
    Lichtnekert, Julia
    Gruener, Sabine
    Green, Luke
    Mattei, Patrizio
    Hartmann, Guido
    Anders, Hans-Joachim
    KIDNEY INTERNATIONAL, 2011, 80 (01) : 68 - 78
  • [8] Phase 1 Clinical Evaluation of the CCR2 Antagonist CCX872-B
    Bekker, Pirow
    Charvat, Trevor
    Miao, Shichang
    Lohr, Lisa
    Sullivan, Timothy
    Miao, Zhenhua
    Powers, Jay
    Jaen, Juan
    Schall, Thomas J.
    DIABETES, 2013, 62 : A292 - A293
  • [9] CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY
    de Zeeuw, Dick
    Henkel, Elena
    Psottova, Jana
    Paragh, Gyorgy
    Mehling, Heidrun
    Hasslacher, Christopher
    Potarca, Antonia
    Bekker, Pirow
    Schall, Thomas J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [10] Renal haemodynamic effects of B2 receptor agonist bradykinin and B2 receptor antagonist HOE 140 in conscious lambs
    Patel, A
    Smith, FG
    EXPERIMENTAL PHYSIOLOGY, 2000, 85 (06) : 811 - 817
12345